Does Medicare cover GLP-1 medicines?
The short answer
Does Medicare cover GLP-1 medicines? It depends on why you take them. Medicare Part D doesn't cover drugs used for weight loss, but it can cover GLP-1s for type 2 diabetes, cardiovascular risk reduction, sleep apnea and MASH. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge lets eligible Part D enrollees get Wegovy, Foundayo or the Zepbound KwikPen for weight management at a $50 copay, according to CMS.
Key takeaways
- Part D excludes drugs used for weight loss, but it can cover GLP-1s for type 2 diabetes.
- The GLP-1 Bridge gives eligible Part D enrollees certain GLP-1s for weight management at $50, through December 31, 2027.
- The reason for your prescription decides the route, so ask your prescriber what the drug is being prescribed for.
- Savings cards don't work with Medicare, and the Bridge copay doesn't count toward your Part D cap.
- Run the Bridge eligibility checker, then take the result to your prescriber.
On this page
- Why doesn’t Medicare Part D cover weight loss drugs?
- What does Part D cover GLP-1s for?
- What is the Medicare GLP-1 Bridge program?
- What will I pay under Part D in 2026?
- What is the negotiated price for semaglutide?
- What is the BALANCE Model?
- Does Medicaid cover GLP-1s for weight loss?
- What are my options if neither Part D nor the Bridge applies?
- How to check where you stand
- Frequently asked questions
- Sources
Medicare GLP-1 Bridge: the rules in CMS's words
| BMI | Plus at least one of |
|---|---|
| 35 or higher | Nothing else needed |
| 30 or higher | heart failure with preserved ejection fraction; uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications); chronic kidney disease stage 3a or above |
| 27 or higher | pre-diabetes (as defined by American Diabetes Association guidelines); previous myocardial infarction; previous stroke; symptomatic peripheral artery disease |
The Bridge covers Foundayo (tablet), Wegovy (injection or tablet) and Zepbound in the KwikPen only. Single-dose Zepbound vials and single-dose Zepbound pens are not covered, and pen needles for the KwikPen are not covered. CMS says the product list may be updated.
The Bridge is a short-term CMS demonstration that runs from July 1, 2026 through December 31, 2027. It is available nationwide, in all states and territories.
You pay a $50 copay for a one-month supply (28 or 30 days, depending on the drug). Because the Bridge runs outside Part D, the $50 does not count toward your Part D deductible or out-of-pocket (TrOOP) costs, Extra Help (the low-income subsidy) does not lower it, it cannot be spread out with the Medicare Prescription Payment Plan, and coupons or discount programs cannot be applied to it.
Each fill is a single monthly supply (28 or 30 days). 60-day and 90-day fills and partial fills are not available. A vacation override exists at the pharmacy, but there is no override for lost or stolen medication.
Your prescriber, not you, submits the prior authorization (electronically or by fax) after the pharmacy has sent a claim to the Bridge and requested it. The decision is sent to the prescriber and mailed to you within 72 hours of submission. An approval is valid through December 31, 2027 and covers refills and dose changes; a new one is needed only if you switch to a different covered GLP-1. There is no appeals process, but the prescriber can resubmit with corrected or additional information.
Your prescriber sends the prescription to a pharmacy, which bills the Bridge's central processor instead of your Part D plan. Pharmacies do not need to opt in to take part. The pharmacy may ask for your Medicare Number or the last 4 digits of your Social Security Number, and it does not need a denial from your Part D plan first.
An approval can stop working before the program ends. If you later fill a GLP-1 through your Part D plan, or move to a plan type that is not eligible, the pharmacy will get a rejection when you try to refill through the Bridge.
CMS does not say what coverage will exist after December 31, 2027. The only statement on the pages read is that the Bridge was extended through that date ahead of a potential, not confirmed, implementation of the BALANCE Model in Part D.
See whether you might qualify with the Bridge eligibility checker.
Medicare’s answer on GLP-1 medicines depends on why the drug is prescribed. For type 2 diabetes and a few other conditions, Part D can cover it like any other drug. For weight loss, the law bars Part D from covering it, and the only Medicare route is a temporary program called the Medicare GLP-1 Bridge. This guide explains both. Every rule comes from CMS (the federal agency that runs Medicare), Medicare.gov or the Federal Register, and each one is quoted in the sources below. The Bridge eligibility checker turns the criteria into a short set of questions.
Why doesn’t Medicare Part D cover weight loss drugs?
Because the law that created Part D excludes them. The legal definition of a covered Part D drug leaves out the drugs and uses that Medicaid may exclude, and that list includes “agents when used for anorexia, weight loss, or weight gain.”
CMS has read that exclusion the same way since Part D began: a drug, when used for weight loss, is not a covered Part D drug. The agency’s reading doesn’t separate people with obesity from people without it.
In November 2024, CMS proposed to reinterpret the law so that Part D and Medicaid would cover anti-obesity medications for people with obesity. It didn’t happen. The final rule published on April 15, 2025 listed that provision among those CMS doesn’t intend to finalize. CMS says Medicare and Medicaid generally don’t cover GLP-1 drugs for weight loss.
What does Part D cover GLP-1s for?
The exclusion is about the use, not the drug itself. Under CMS policy, an anti-obesity medication can be covered in Part D if it’s being used to treat another medically accepted indication (an accepted medical use). CMS names these as eligible for Part D coverage:
- type 2 diabetes
- reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight (CMS gives Wegovy as the example)
- moderate to severe obstructive sleep apnea in adults with obesity (CMS gives Zepbound as the example)
- noncirrhotic MASH with moderate to advanced liver scarring
“Coverable” isn’t the same as “on your plan’s formulary,” the plan’s list of covered drugs. CMS says these uses are coverable under the basic Part D benefit whether or not the drug is on the plan’s formulary, and that plans must keep following their formulary exception processes for these requests. In practice, your prescriber may need to submit a prior authorization (the plan’s approval before it pays) or an exception request, and your cost depends on the plan’s tier for the drug.
If you already get a GLP-1 through your Part D plan for one of these conditions, CMS’s instruction is to keep getting it through the plan. The pages on Wegovy and Zepbound go through each drug.
What is the Medicare GLP-1 Bridge program?
The Bridge is a short-term demonstration run by CMS. It gives eligible Part D beneficiaries access to certain GLP-1 drugs for weight management between July 1, 2026 and December 31, 2027, nationwide, in all states and territories.
The essentials:
- Copay. $50 for a one-month supply (28 or 30 days, depending on the drug), paid to the pharmacy.
- Covered products. All formulations of Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound. Zepbound single-dose vials and single-dose pens aren’t available. CMS says the list may change.
- One prior authorization. Your prescriber submits it. An approval is valid through December 31, 2027 and covers refills and dose changes, unless you switch to a different covered GLP-1.
- Outside Part D. The Bridge runs outside the Part D benefit, so plans don’t have to opt in and pharmacies don’t need to opt in either. The pharmacy bills the Bridge’s central processor instead of your plan.
Behind the copay, participating manufacturers provide the drugs at a net price of $245 per monthly supply. None of that counts toward your Part D drug costs.
Who is eligible?
You must be 18 or older and enrolled in Part D through a standalone drug plan or a Medicare Advantage coordinated care plan with drug coverage. Special Needs Plans, employer or union group waiver plans and the LI NET program count. If your only coverage is a private fee-for-service plan, a cost contract plan, a health care prepayment plan, a PACE organization, a fallback plan or a religious fraternal benefit plan, you’re not eligible unless you’re also enrolled in a standalone drug plan.
The drug must be prescribed to reduce excess body weight and maintain the reduction, together with lifestyle modification that includes structured nutrition and physical activity. You must also meet one of three BMI tiers, measured at the time you first started GLP-1 therapy:
- BMI of 35 or higher, with no other condition needed
- BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above
- BMI of 27 or higher with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease
Who is excluded?
- Anyone whose Part D plan has paid for a GLP-1 in 2026, for any reason. CMS reviews its data for this, and sets the lookback period that applies in 2027.
- People with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH with moderate to advanced liver scarring, whether or not their plan covers a GLP-1 for it. Those requests go to the Part D plan.
- Prescriptions written in order to reduce cardiovascular risk. Having had a heart attack or stroke doesn’t rule you out, but if the drug is prescribed for that purpose, CMS says it should be routed to the Part D plan.
The full Bridge explainer takes each criterion in turn, including what happens if you lose eligibility partway through.
What will I pay under Part D in 2026?
If your Part D plan covers your GLP-1 for a covered use, the standard Part D cost rules apply. For 2026:
- Deductible. This is what you pay before the plan starts paying. No Medicare drug plan may have a deductible of more than $615 ($700 in 2027). Some plans have none.
- Coinsurance. After the deductible, you pay 25% of the cost of your generic and brand-name drugs until your out-of-pocket spending on covered Part D drugs reaches the cap.
- Out-of-pocket cap. $2,100 in 2026 ($2,400 in 2027). After that you pay nothing for covered Part D drugs for the rest of the calendar year.
- Payment plan. The Medicare Prescription Payment Plan lets you spread out-of-pocket costs for plan-covered drugs across the calendar year. All plans offer it. Joining is voluntary and costs nothing, and it doesn’t lower your drug costs.
- Extra Help. A Medicare program that helps people with limited income and resources pay Part D premiums, deductibles and coinsurance. The 2026 limits are $23,940 in income and $18,090 in resources for an individual, and $32,460 and $36,100 for a married couple.
None of these apply to the Bridge. The Bridge copay doesn’t count toward the deductible or the cap, Extra Help doesn’t reduce it, and you can’t put it on the payment plan. The Part D costs page works through what this means for a GLP-1.
What is the negotiated price for semaglutide?
Semaglutide (Ozempic, Rybelsus and Wegovy) is one of the drugs in the Medicare Drug Price Negotiation Program. CMS and Novo Nordisk agreed on a negotiated price, which the law calls a maximum fair price, of $274 for a 30-day supply for 2027. CMS compares that with a 2024 list price of $959, a 71% discount. The negotiated prices take effect on January 1, 2027, and by law Part D plans must include the selected drugs on their formularies.
Two cautions. This is a negotiated price for the drug, not a copay. The CMS fact sheet doesn’t say what a beneficiary will pay at the counter, which is still set by your plan’s benefit. And a negotiated price doesn’t change the weight-loss exclusion. CMS lists a maximum fair price of $385.63 for a package of four Wegovy 2.4 mg pens, but that’s a Part D price for Part D covered uses. It doesn’t by itself make Wegovy covered for weight loss.
What is the BALANCE Model?
BALANCE is a voluntary CMS Innovation Center model. Under it, CMS negotiates GLP-1 pricing and coverage terms with manufacturers on behalf of state Medicaid agencies and Part D plan sponsors. When CMS announced it on December 23, 2025, the plan was a Medicaid launch as early as May 2026 and a Part D launch in January 2027.
The Medicare side hasn’t gone ahead on that schedule. CMS’s BALANCE page refers to the model not launching in Medicare in 2027, and says the Bridge has been extended through December 31, 2027 ahead of a potential implementation of BALANCE in Part D. “Potential” is CMS’s word. The BALANCE page has the timeline.
Does Medicaid cover GLP-1s for weight loss?
It depends on your state. Covering drugs used for weight loss is optional for state Medicaid programs, so some do and some don’t. State Medicaid agencies can join BALANCE from May 2026 through January 1, 2027, and CMS says the model doesn’t guarantee coverage for any individual. See Medicaid coverage for what the federal sources say and how to check your state.
What are my options if neither Part D nor the Bridge applies?
Manufacturer savings cards are closed to Medicare enrollees, so the remaining route is paying cash through a manufacturer self-pay program, where its eligibility terms allow. Those programs start at $149 a month for the Wegovy pill and $299 for Zepbound. You don’t use insurance, the cost isn’t reimbursed, and it doesn’t count toward your Part D limits.
Read the eligibility terms before you rely on a price. The TrumpRx listings for Wegovy and Ozempic, for example, exclude government beneficiaries. The GLP-1 cost guide and the without-insurance page set out the prices. Before you pay cash, ask your prescriber whether any Part D covered use applies to you, because that changes which door you use.
How to check where you stand
- Find your plan type. If you’re not sure what kind of Medicare drug coverage you have, Medicare says to call 1-800-MEDICARE (1-800-633-4227).
- Ask your prescriber what the drug is being prescribed for. That decides whether the request goes to your Part D plan or to the Bridge.
- For weight management, run the eligibility checker and take the result to your prescriber, who sends the prescription to the pharmacy and completes the prior authorization when the pharmacy requests it.
- For a Part D covered use, ask the plan whether the drug is on the formulary, what tier it’s on, and whether you need prior authorization or a formulary exception.
Frequently asked questions
Does Medicare cover GLP-1 drugs for weight loss?
Not through Part D itself. The Part D law excludes agents when used for weight loss, and CMS says Medicare generally doesn't cover GLP-1s for weight loss. The exception is the Medicare GLP-1 Bridge, a temporary CMS demonstration running July 1, 2026 through December 31, 2027. It provides certain GLP-1s for weight management to eligible Part D enrollees for a $50 copay.
Does Medicare cover Wegovy?
It can, in two ways. Part D can cover Wegovy when it's prescribed to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. For weight management, eligible Part D enrollees can get the Wegovy pen or pill through the Medicare GLP-1 Bridge for $50 per one-month supply.
Does Medicare cover Zepbound?
Part D can cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. For weight management, the Medicare GLP-1 Bridge covers only the Zepbound KwikPen, at $50 per one-month supply. You can't get single-dose vials or single-dose pens through the Bridge, and pen needles aren't covered.
Does Medicare cover Ozempic or Mounjaro?
CMS says type 2 diabetes is a use eligible for Part D coverage, so a GLP-1 prescribed for type 2 diabetes goes through your Part D plan under its formulary and rules. Ozempic and Mounjaro aren't on the Bridge's list of covered products, and people with type 2 diabetes aren't eligible for the Bridge.
Who qualifies for the Medicare GLP-1 Bridge?
You need to be 18 or older, enrolled in an eligible Part D plan, and prescribed a covered GLP-1 for weight management alongside lifestyle modification. You also need a BMI of 35 or higher, or 30 or higher with a listed condition, or 27 or higher with a listed condition, at the time GLP-1 therapy began. People with type 2 diabetes, moderate to severe sleep apnea or MASH aren't eligible.
Does the $50 Bridge copay count toward my Part D out-of-pocket cap?
No. Bridge drugs are provided outside the Part D benefit. The Part D deductible doesn't apply, and no part of the $50 copay counts toward your true out-of-pocket costs. Extra Help doesn't lower it, and you can't spread it out with the Medicare Prescription Payment Plan. Coupons and discount programs can't be applied to Bridge claims.
What is the Part D out-of-pocket cap in 2026?
For drugs your Part D plan covers, out-of-pocket spending is capped at $2,100 in 2026 ($2,400 in 2027). After you reach the cap, you pay nothing for covered Part D drugs for the rest of the calendar year. No plan may have a deductible above $615 in 2026. These limits apply to Part D covered drugs, not to Bridge fills.
Will Medicare cover weight loss drugs after 2027?
CMS hasn't said what coverage will exist after December 31, 2027. The Bridge was extended through that date ahead of a potential, not confirmed, implementation of the BALANCE Model in Part D. Separately, a 2024 proposal to let Part D cover anti-obesity medications for obesity wasn't finalized.
Can I use a manufacturer savings card with Medicare?
No. The Lilly and Novo Nordisk savings cards exclude people enrolled in Medicare, Medicare Part D, Medicare Advantage and other government programs, and CMS says coupons and discount programs may not be applied to Bridge claims. Your options are your Part D plan for covered uses, the Bridge for weight management, or a manufacturer's self-pay program where its terms allow.
Sources (24)
- 1.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 2.CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
“Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
- 3.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (final rule, 90 FR 15792)
“We also do not intend to finalize the following provisions from the proposed rule: Enhancing Health Equity Analyses: Annual Health Equity Analysis of Utilization Management Policies and Procedures, Part D Coverage of Anti-Obesity Medications (AOMs) and Application to the Medicaid Program, and Ensuring Equitable Access to Medicare Advantage Services—Guardrails for Artificial Intelligence (AI).”
- 4.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 5.CMS: Information for Part D Plans
“Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
- 6.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
- 7.CMS: Information for Part D Plans
“Under the Medicare GLP-1 Bridge, participating manufacturers will provide eligible GLP-1 drugs at a net price of $245 per monthly supply. Coverage of eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge is provided outside of the Part D benefit payment flow and coverage. As such, no part of the $245 net price for eligible GLP-1 drugs prescribed for uses covered under the Medicare GLP-1 Bridge would count toward an eligible beneficiary’s gross covered prescription drug costs (GCPDC), and no part of the $50 copay would count toward the beneficiary’s true out-of-pocket costs (TrOOP) under their Part D plan.”
- 8.CMS: Information for Part D Plans
“CMS will be utilizing Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Medicare GLP-1 Bridge. [...] The Medicare GLP-1 Bridge will be the primary payer for products covered under the Medicare GLP-1 Bridge and will not coordinate benefits with other payers.”
- 9.CMS: Medicare GLP-1 Bridge
“The Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit’s coverage and payment flow. As a result, Part D sponsors will not carry risk for eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge, and Part D sponsors do not have to opt in to the Medicare GLP-1 Bridge for eligible beneficiaries to access these drugs beginning July 1, 2026.”
- 10.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“The BALANCE Model, which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, aims to increase access to select glucagon‐like peptide‐1 (GLP-1) medications and healthy lifestyle interventions — to help people with Medicare and Medicaid improve their health. As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors.”
- 11.CMS: CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines, Promote Healthier Living
“Participation will be voluntary for manufacturers, states, and plans. Additional information will be released in early 2026 regarding state and Part D plan participation. The BALANCE Model will launch in Medicaid as early as May 2026 and in Medicare Part D in January 2027.”
- 12.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“Will the Medicare GLP-1 Bridge continue into 2027? Yes. The Medicare GLP-1 Bridge has been extended through December 31, 2027. [...] What is the impact of the BALANCE Model not launching in Medicare in 2027 on the Medicare GLP-1 Bridge? The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D.”
- 13.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“Currently, state Medicaid programs have discretion to cover the drugs or classes of drugs listed in section 1927(d)(2) of the Act, including “agents used for . . . weight loss . . .””
- 14.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“State Medicaid agencies can join the model beginning in May 2026 through January 1, 2027. [...] Coverage in the Medicaid program will depend on participation by drug manufacturers and states. Patients would be subject to qualifications set by the negotiations between CMS and participating manufacturers, including certain prior authorization requirements. Therefore, this model will not guarantee coverage for any individual.”
- 15.Medicare.gov: How much does Medicare drug coverage cost?
“After you reach your full deductible (if your plan has a deductible), you’ll pay 25% of the cost as coinsurance for your generic and brand-name drugs until your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027)(including certain payments made on your behalf, like through the Extra Help program). Then, you’ll automatically get “catastrophic coverage.” Catastrophic coverage stage: You won’t have to pay out-of-pocket for covered Part D drugs for the rest of the calendar year.”
- 16.Medicare.gov: How much does Medicare drug coverage cost?
“No Medicare drug plan may have a deductible more than $615 in 2026 ($700 in 2027). Some Medicare drug plans don’t have a deductible.”
- 17.Medicare.gov: What’s the Medicare Prescription Payment Plan?
“The Medicare Prescription Payment Plan is a payment option that works with your current drug coverage to help you manage your out-of-pocket costs for drugs covered by your plan by spreading them across the calendar year (January–December). [...] All plans offer this payment option, and participation is voluntary. [...] There’s no cost to participate in the Medicare Prescription Payment Plan. [...] This payment option might help you manage your monthly expenses, but it doesn’t save you money or lower your drug costs.”
- 18.Medicare.gov: Help with drug costs
“"Extra Help" is a Medicare program to help people with limited income and resources pay Medicare drug coverage (Part D) premiums, deductibles, coinsurance, and other costs. [...] Income and resource limits in 2026: [table] Individual: Income limit $23,940, Resource limit $18,090. Married couple: Income limit $32,460, Resource limit $36,100.”
- 19.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
- 20.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“For example, for the selected drug with the highest total gross covered prescription drug costs under Part D in 2024, Ozempic; Rybelsus; Wegovy, the MFP applied across three commonly used dosage forms and strengths will be: [table] NDC-11: 00169-4524-14. Description of package: 2.4mg/0.75mL Pen, 4 Pens (Wegovy). MFP per package: $385.63.”
- 21.CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
“These negotiated prices will become effective on January 1, 2027. [...] As required by law, Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage-prescription drug plans, must include in their formularies the selected drugs for which CMS and the participating drug company have agreed to a negotiated price.”
- 22.
- 23.
- 24.
